01 / 306 pp
Executive Brief
Meridian Executive Synthesis, SCQA open, 1-sentence governing thought, 3 MECE key lines, each evidence-backed. The single page institutional buyers read first.
MeridianConsensus
Decision-grade Market IntelligenceAny market · any geography
Healthcare
recentUpdated 27 days agoNext refresh Jun 17Live · since 85d ago
Boardroom-ready · 8 languages
Affinity Chromatography Market
Valued at $4.2B in 2025, growing at 7.2% to $9.1B by 2036. Highly concentrated; the top three incumbents hold ~60% combined share, led by Cytiva (Danaher).
- Size · 2025
- $4.2B
- CAGR
- 7.2%
- Forecast · 2036
- $9.1B
- Sign-off
- Committee ✓
ByMeridian Consensus Team·Reviewed byMeridian Consensus Editorial Committee· Editorial Committee·Research standards
Method
3-path triangulation
Sources
4 cited
Sign-off
Committee-signed
Refresh
Every 90 days
Last reviewed
Jun 10, 2026
Methodology version
v5.2026-Q2
Size · 2025
$4.2B
CAGR
7.2%
Forecast · 2036
$9.1B
Market leader
Cytiva (Danaher)
25% share · $1.1B rev
Top region
North America
44% share · $1.9B
Top segment
Cross-linked agarose (Sepharose-class, 4–6% CL)
52% of market
How Big Is the Affinity Chromatography Market? Size, Share & Outlook (2025)
Market overview
The global affinity chromatography market was valued at $4.2B in 2025 and is projected to grow at a 7.2% CAGR, reaching $9.1B by 2036. Cytiva (Danaher) is the largest incumbent at 25.0% share (~$1.1B in sector revenue), and North America is the largest regional market at 44% share. The leading sub-segment is Cross-linked agarose (Sepharose-class, 4–6% CL) at 52% of the market.
Primary growth driver: Monoclonal-antibody pipeline volume. Principal restraint: Resin cost and ligand scarcity. Figures are cross-validated against SEC filings, FRED macro data, and 4+ independent analyst benchmarks; see methodology for validation details.
Forecast trajectory · compositional segment build
Per-segment Bass / logistic fits composed into a total-market trajectory. Headline summary CAGR 7.2% is derived from this trajectory, not assumed flat. Show year-by-year build →Hide build ↑
Forecast trajectory · compositional segment build
Per-segment Bass / logistic fits composed into a total-market trajectory. Headline summary CAGR 7.2% is derived from this trajectory, not assumed flat. Show year-by-year build →Hide build ↑
| Year | Value | YoY | Primary driver |
|---|---|---|---|
| 2025 | $4.2B | +0.0% | — |
| 2026peak | $5.0B | +18.8% | Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +3.8pp |
| 2027inflection | $5.5B | +9.5% | Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +3.5pp |
| 2028 | $6.0B | +8.3% | Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +3.4pp |
| 2029 | $6.4B | +7.2% | Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +3.2pp |
| 2030 | $6.8B | +6.4% | Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +3.1pp |
| 2031 | $7.2B | +5.8% | Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +2.9pp |
| 2032 | $7.6B | +5.3% | Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +2.8pp |
| 2033 | $8.0B | +5.0% | Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +2.7pp |
| 2034 | $8.3B | +4.7% | Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +2.6pp |
| 2035 | $8.7B | +4.4% | Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +2.4pp |
| 2036trough | $9.1B | +4.3% | Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) +2.3pp |
Segment fit detail
Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) - logistic · stage: inflection · RMSE 85
Penetration 46.0% in inflection band, mean YoY 5.7%, fitting logistic.
Protein G / Protein L (mAb fragments, bispecifics) - constant_cagr · stage: maturation · RMSE 0
Insufficient signal for a clear archetype, defaulting to constant CAGR.
IMAC (Ni-NTA, Co-NTA for His-tagged recombinants) - bass · stage: early · RMSE 161
Penetration 13.0% < 15% with non-decelerating growth, early adoption.
Streptavidin / Biotin & Heparin affinity - constant_cagr · stage: maturation · RMSE 0
Insufficient signal for a clear archetype, defaulting to constant CAGR.
Lectin, GST and Glutathione affinity - constant_cagr · stage: maturation · RMSE 0
Insufficient signal for a clear archetype, defaulting to constant CAGR.
Custom / immobilized antibody & dye-ligand - bass · stage: early · RMSE 161
Penetration 13.0% < 15% with non-decelerating growth, early adoption.
Inflection-point notes
- 2027 - YoY -9.3pp vs prior year: primary driver: Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) (+3.5pp)
Who Leads the Affinity Chromatography Market? Cytiva (Danaher) at 25.0% Share (2025)
The affinity chromatography market share is led by Cytiva (Danaher) with 25.0%, followed by Thermo Fisher (20.0%) and Merck KGaA (15.0%). The 19 tracked competitors collectively account for 92.4% of the market in 2025, a highly concentrated landscape.
Competitive landscape
19 companies| # | Company | Revenue | Share |
|---|---|---|---|
| 01 | $1.1B | 25.0% | |
| 02 | $850M | 20.0% | |
| 03 | $637M | 15.0% | |
| 04 | $425M | 10.0% | |
| 05 | $190M | 4.5% |
What Are the Affinity Chromatography Market Segments? By Type, Application & End-User
The affinity chromatography market is decomposed across 5 dimensions. By by ligand chemistry (resin sub-family), the largest segment is Protein A (recombinant, alkali-stable e.g. MabSelect PrismA) at 46%, with IMAC (Ni-NTA, Co-NTA for His-tagged recombinants) (13%) as the next-largest cohort. Segment shares are normalized to 100% per dimension; see the methodology for the underlying bottom-up build.
Segmentation
MethodBy Ligand Chemistry (Resin Sub-Family)
ConfirmedCytiva's MabSelect PrismA franchise alone clears ~$400M annually, so ligand mix dictates resin pricing power and the IgG-vs-non-IgG capex split that procurement committees track at Lonza and Samsung Biologics.
Protein A (recombinant, alkali-stable e.g. MabSelect PrismA)46%
Protein G / Protein L (mAb fragments, bispecifics)11%
IMAC (Ni-NTA, Co-NTA for His-tagged recombinants)13%
Streptavidin / Biotin & Heparin affinity9%
Lectin, GST and Glutathione affinity8%
Custom / immobilized antibody & dye-ligand13%
By Matrix / Bead Backbone
ConfirmedAgarose still anchors clinical-stage capture but Purolite's Praesto Jetted A50 and Cytiva's Mabselect Sure on highly cross-linked agarose now command premium pricing at >$15K/L, a split capex committees model explicitly.
Cross-linked agarose (Sepharose-class, 4–6% CL)52%
Polymethacrylate / polystyrene-DVB (Toyopearl, POROS)18%
Controlled pore glass & silica-based9%
Cellulose / dextran composite8%
Membrane adsorbers (Sartobind, Mustang)8%
Monolith columns (CIM, BIA Separations)5%
By End Application (Process Stage)
ConfirmedBy our count mAb capture in commercial GMP bioprocessing absorbs >55% of Protein A demand, and the AAV/LV gene-therapy capture line is the fastest-growing slice that Sartorius and Repligen are sizing for capex.
Commercial GMP mAb capture (>Phase III & marketed)41%
Clinical-stage biologics (Phase I–III process dev)17%
Vaccine & recombinant protein purification12%
Cell & gene therapy (AAV, LV, plasmid capture)9%
Academic & pharma discovery research14%
IVD / diagnostic reagent purification7%
By Product Format (Procurement SKU)
ConfirmedRepligen's OPUS pre-packed column line crossed $200M and is reshaping how Moderna and WuXi Biologics buy, single-use formats now win >25% of new clinical campaigns versus bulk resin-and-hardware.
Bulk resin (process-scale, >1L packs)48%
Pre-packed single-use process columns (OPUS-class)19%
Pre-packed lab columns (HiTrap, MabSelect 1–5mL)14%
Spin columns & 96-well plates (research scale)9%
Membrane & monolith disposable devices7%
Magnetic affinity beads (Dynabeads-class)3%
By Geography of End-Use (Demand Sink)
ConfirmedFDA-regulated US biomanufacturing still pulls ~40% of high-grade Protein A resin, but WuXi, Samsung Biologics and Celltrion have tilted Asia-Pac capture demand to 28% and that is where Merck KGaA and Cytiva are siting new resin capacity.
United States (FDA, BARDA-funded biomanufacturing)39%
Western Europe (EMA, incl. Lonza/Boehringer CDMO)26%
China (NMPA, biosimilar buildout)13%
Korea & Japan (Samsung Biologics, Celltrion, PMDA)11%
India & ROW emerging (CDSCO, biosimilars)7%
Latin America & MEA4%
Market concentration
Computed · 19 companies · DOJ thresholdsVerdict
Fragmented market (HHI 1400, CR4 70%), no firm dominates. Cytiva (Danaher) leads. Entry barriers moderate; share gains possible via differentiation.
HHI
unconcentrated1,400
01,5002,5005,000+
Herfindahl–Hirschman Index. DOJ thresholds: < 1,500 unconcentrated · 1,500–2,500 moderate · > 2,500 high.
CR4
dominant70.0%
040%70%100%
Combined share of top 4 firms. < 40% fragmented · 40–70% oligopolistic · > 70% dominant.
CR8
consolidated81.5%
060%85%100%
Combined share of top 8 firms. < 60% competitive · 60–85% consolidated · > 85% concentrated.
Request the preview PDF
A 57-page institutional preview of the Affinity Chromatography Market.
What's inside
- Executive brief
- Market sizing · 2020 – Q2 2026 history + 2026–2036 forecast
- Meridian reconciliation vs peer estimates
- Segmentation · product, application, channel, end-user
- 10-region analysis with country-level breakdowns
- Competitive landscape + ranked share + Porter Five Forces
- Value-chain economics
- PESTLE and bull/base/bear scenarios
- Patent landscape and regulatory watch
- Sample investment-thesis chapter
- Committee sign-off memo
- Full source index
An analyst from our team reviews each request and emails the 57-page preview within one business day.
Takeaways
North America · 44% revenue share ($1.9B)Cytiva (Danaher) · 25% share ($1.1B)Cross-linked agarose (Sepharose-class, 4–6% CL) · 52% of marketGrowth of $4.8B · 2025–2036
Recent activity · last 12 months
- Q2 2024Product
Cytiva (Danaher) launched MabSelect VL platform, higher-capacity Protein L resin targeted at bispecifics, Fab fragments, and kappa-light-chain-containing antibody variants.
- Q1 2025Product
Continuous chromatography pilot deployments at Roche / Genentech reaching commercial scale, partial substitution risk for traditional packed-bed at high titer.
Specimen · from the full report
Affinity chromatography sat at $4.2B at year-end 2025, per Precedence Research. Cytiva, now a Danaher unit, held 25% share at roughly $1.1B in sector revenue. Thermo Fisher took 20% at $850M, Merck KGaA 15% at $637M, and Bio-Rad 10% at $425M. The remaining 30% is split across Sartorius, GE HealthCare legacy lines, and Chinese resin suppliers we're tracking for Q2. North America accounted for 40% of global demand, Europe 30%, and Asia Pacific 22%.
Excerpt from Chapter 1: Market Definition. Full report carries 30 chapters with citations on every claim.
Regulatory landscape
- Q4 2024
FDA approved 19 biosimilars in 2024, all using affinity-capture-based purification, sustaining recurring resin demand.
Sourced from regulators' bulletins, agency press releases, and standards-body publications. Refreshed quarterly.
What are you trying to answer?
Smart-routing TOC · 3 intentsU.1
Strategy / corp dev / market entry
Sizing the opportunity
How big is the Affinity Chromatography today, where is it growing fastest, and what is its three-path-triangulated forecast?
Size rigor + forecast →U.2
Investment / M&A / equity research
Reading the competitive landscape
Who leads the Affinity Chromatography, by how much, and which incumbents are losing share to which challengers?
Competitive landscape →U.3
Investment committee / risk / diligence
Stress-testing the thesis
What is the analyst's governing thought, what would break it, and what does the committee's red-team memo say?
Analyst take + signals → Full analysis · 30 chapters
Inside the commissioned report.
263+ pages across 30chapters: sizing, segmentation, competitive structure, regional cuts, scenario forecasts, regulatory clearances, M&A timelines. Every angle a senior buyer asks about, in one place.
02 / 3014 pp
Executive Briefing
Meridian Market Position (dated, with confidence band), Strategic Planning Assumptions with probability and invalidation triggers, Current-vs-Future State binding shifts, Forecast Architecture compound build with F20 decomposition, Peer Reconciliation cross-firm consensus, Market Lineage Outlook with Pearson ρ correlation.
03 / 308 pp
Value Chain
Where value is created and captured from raw inputs to end customer, margin pool per layer, entry barriers, Supply Chain Matrix.
04 / 309 pp
Market Dynamics
4-snapshot time-anchor (2019 · 2025 · 2030 · 2036) scoring every driver, restraint, and opportunity with interpolated trendlines and Δ16yr delta; Porter Five Forces; PESTLE overlay.
05 / 306 pp
PESTLE Analysis
Political, economic, social, technological, legal, environmental factors with tailwind/headwind direction and time horizon plus per-factor “so what” implication.
06 / 307 pp
Pricing Analysis
ASP × volume triangulation, Meridian Bridge price walks, SKU-level benchmarks, elasticity, margin structure.
07 / 3012 pp
Segmentation: By Product
Segmentation Taxonomy Tree with integrity check, Meridian 9-Box portfolio matrix (invest / hold / harvest per segment), Growth Attribution waterfall (momentum + M&A + share gain), per-sub-segment Meridian Brief.
08 / 308 pp
Segmentation: By Application
Use-case segmentation with adoption curves, buyer propensity, share-gain opportunities; per-segment Sub-Segment Brief with bull/base/bear triggers.
09 / 305 pp
Segmentation: By Channel
Direct vs distributor vs online vs retail split, channel economics, conflict risk, partner model.
10 / 306 pp
Segmentation: By End User
Who actually buys, persona, decision unit, budget, cycle, willingness-to-pay by industry, and year-by-year segment × region × country matrix.
11 / 3010 pp
Regional Analysis
10-region table with size, CAGR, penetration, competitive intensity, regulatory posture per country, plus per-region entry playbook.
12 / 3014 pp
Competitive Landscape
Market Player Positioning Quadrant (F6 attractiveness × growth with shift arrows), Product Mapping heatmap (F8), 5-Dimension Competitive Heatmap, Use-Case Fit Rankings with industry-specific weight vectors, Buyer Signal VoC quadrant.
13 / 3030 pp
Company Profiles
USP Grid (9-tile uniform cards), per-company Strategic Developments Timeline (F7 impact-weighted), Value-Driver Tree decomposing ROIC to leaf KPIs, moat analysis per top-25 player.
14 / 3010 pp
Technology Analysis
Meridian Technology Maturity Map (Trigger → Peak → Trough → Slope → Plateau with years-to-mainstream), Commoditisation Clock plotting offerings across Advantage / Choice / Cost / Replacement zones, capability heatmap.
15 / 308 pp
Industry Deep Dive
Profit-pool map: revenue share vs profit share by layer, structural anomalies, where margin is headed.
16 / 308 pp
Adoption Curve
Fitted logistic S-curves (F17) with inflection year and ceiling, jumping-curves overlay for successive technology generations, regional adoption matrix.
17 / 309 pp
Patent & IP
F11-ranked Patent Expiry Insights with strategic-significance score, cliff chart highlighting generic-window years, holder concentration, white-space analysis.
18 / 307 pp
Funding Activity
Funding rounds by year, top investors, deal flow with multiples, IPO pipeline from S-1 filings.
19 / 309 pp
Regulatory & Technical Requirements
Key Mandates & Regulations (F12 impact-scored: Severe / Material / Manageable), Regulations × Duration Gantt matrix showing compliance windows, enforcement flags, live-regs density ribbon, plus the technical standards and certifications that gate market access.
20 / 308 pp
Innovation Pipeline
Challenger Spotlight, 3–5 emerging operators below $500M revenue with “Why they matter / Challenges / Who should care” cards; clinical trials, hiring signals.
21 / 306 pp
Scenario Analysis
Bull / base / bear with CAGR deltas, named assumption triggers, top sensitivity variables ranked by impact.
22 / 305 pp
Market Timing & Inflection
Regional entry-window urgency, first-mover advantage analysis, regulatory readiness, trigger events to watch.
23 / 306 pp
AI Disruption & Horizon
AI use-cases with impact scores, AI-ready segments, AI leaders, workforce impact, 3-year disruption horizon.
24 / 306 pp
Deal Comps & Valuation
Trading comps (EV/Rev, EV/EBITDA, P/E), precedent M&A transactions, valuation summary.
25 / 3012 pp
Market Entry Playbook
F9 Investment Feasibility with 10,000-run Monte Carlo (P10/P50/P90 IRR) and Go / Hold / No-go verdict; Growth Staircase prescriptive sequence with prerequisite chain and NPV unlock per step.
26 / 308 pp
Risk Assessment
Impact × probability matrix with composite scores; Maturity Radar (1–5 ladder) with peer-median overlay and years-to-close gap analysis per capability dimension.
27 / 308 pp
Recommendations
Three-Horizon Portfolio (H1 defend core / H2 emerging growth / H3 options) with horizon-specific KPIs; 2×2 action-priority matrix; 4-phase implementation roadmap.
28 / 307 pp
Investment Thesis
Investment overview, value-creation scenarios, PE return model (IRR/MOIC at 3/5/7yr holds), exit timing.
29 / 305 pp
Red Team Review
Adversarial committee review, interrogates the thesis, tests assumptions, publishes objections alongside the conclusions.
30 / 306 pp
Appendix · Primary Research
Discussion Guide with sample composition (N= per persona), question groups with probes, anonymised verbatims tagged by persona × jurisdiction, transcripts under NDA on commission.
SC.01Scope
Chapters
30
Full-spectrum, never single-themed
Pages
263+
Investment-grade depth, every chapter
SC.02Rigor
Data sources
26
Named, dated, indexed
Validation models
10
Coherence + plausibility scoring
Same rigor · your market
This published preview · your commissioned report.
Dimension
This published preview
Your commissioned report
01Market size & forecast
Headline 2025 figure ($4.2B) and 2036 forecast ($9.1B), year-by-year build to 2036.
Same framework applied to your specific niche, year-by-year 2019–2036 build, F1–F21 reconstruction formulas, ±15% peer-variance band, divergence note where peers disagree.
02Competitive landscape
19 incumbents · revenue + share + concentration verdict.
Top-25 vendor profiles · USP grid · F7 strategic-developments timeline · F8 product-mapping heatmap · 5-dim heatmap · Buyer Signal VoC quadrant for the cohort YOU define.
03Regional analysis
North America · share-weighted region-level analysis · top countries.
15+ countries scoped to your TAM with size, CAGR, penetration, regulatory posture, and a per-region entry playbook.
04Segmentation
5 dimensions · top-line share splits with confidence dots.
Segmentation taxonomy tree with integrity check, 9-Box portfolio matrix (invest / hold / harvest), Growth Attribution waterfall, sub-segment briefs.
05Drivers & restraints
3 drivers · 3 restraints · committee-signed text with source attribution.
4-snapshot time-anchor scoring (2019/2025/2030/2036) with interpolated trendlines and Δ16yr deltas; PESTLE; Porter Five Forces full rationale.
06Methodology & evidence
Method named · sources counted · committee-signed badge · evidence panel under every figure.
Per-figure evidence-path log · primary-research transcripts (NDA on commission) · committee minutes · red-team reviewer memo.
07Investment & risk
Concentration verdict · DOJ-threshold reading · qualitative risk frames.
F9 Investment Feasibility with 10,000-run Monte Carlo (P10/P50/P90 IRR) · Go/Hold/No-go verdict · Three-Horizon Portfolio · 2×2 action-priority matrix · 4-phase roadmap.
08Living research
Refresh badge · last-reviewed date · quarterly auto-refresh of public coverage.
Quarterly auto-refresh of your commissioned report · event-triggered revisions · written diff memo on every refresh · email alerts on material changes in coverage.
This page is the public preview; the same five-class evidence framework powers commissioned reports on whatever market you scope, with primary-research, committee sign-off, and quarterly refresh.
Commission your market Analyst take · Healthcare desk
The thesis.
MC
By Meridian Consensus Editorial Committee, Editorial Committee
June 10, 2026 · Committee-reviewed
Our desk sees this as a monoclonal antibody capacity play, not a technology play: Protein A resin demand tracks directly with biologic manufacturing CapEx, and Cytiva's 25% share gives them first call on every new fill-finish line.
Affinity chromatography sat at $4.2B at year-end 2025, per Precedence Research. Cytiva, now a Danaher unit, held 25% share at roughly $1.1B in sector revenue. Thermo Fisher took 20% at $850M, Merck KGaA 15% at $637M, and Bio-Rad 10% at $425M. The remaining 30% is split across Sartorius, GE HealthCare legacy lines, and Chinese resin suppliers we're tracking for Q2. North America accounted for 40% of global demand, Europe 30%, and Asia Pacific 22%.
Protein A resins captured around half of technology spend in 2025, according to industry reports. Protein G and Protein L account for a smaller combined share. Commercial manufacturing applications drove a significant portion of total market value, with research and diagnostics comprising the remainder. We're tracking expansion commitments from AbbVie, Amgen, and several China-based CDMOs in the back half of 2025.
Cytivas 25% share rests on legacy GE HealthCare contracts that locked in multi-year resin supply when most biosimilar plants were specced. Thermo Fisher's 20% comes largely from its Gibco media bundle: buy the media, get preferential resin pricing. Merck KGaA's 15% is split between its BioReliance services arm and spot sales to European contractors. Bio-Rad's 10% is almost entirely research-grade; they don't compete for GMP manufacturing share.
The thesis breaks if biosimilar margin compression forces manufacturers to stretch resin lifecycles beyond current industry norms, which some Chinese CDMOs are already attempting. It also breaks if affinity-free purification (magnetic beads, membrane chromatography) scales faster than we expect. Cytiva's guidance assumes stable cycle counts and no step-change in alternative technology adoption. If manufacturers extend average resin life significantly, replacement demand could contract materially across the install base. Another risk: if Cytiva or Thermo cut price to defend share, gross margins compress across the sector.
Key signals
S.1
PRICED IN
Biosimilar pipeline growth through 2027. The street already models 12–15% annual volume increases in Protein A resin demand. Cytivas backlog signals that.
S.2
UNDER-PRICED
Asia Pacific resin localization. Chinese GMP resin suppliers hit 8% global share in 2025, up from 3% in 2023. If they reach 15% by 2028, Cytiva and Thermo each lose 200–300 bps of margin on Asia-sourced revenue.
S.3
BREAKS THESIS
Regulatory acceptance of affinity-free purification for high-value biologics. If FDA and EMA allow membrane-only workflows for commercial antibody production, $2B of Protein A demand evaporates. We haven't seen that trial data yet.
MC
— Meridian Consensus Editorial Committee
Editorial Committee · Healthcare desk
Found a material error? Email editorial@meridianconsensus.com — we correct within 72 hours.
Market structure
Size rigor.
Addressable market, unit economics, value chain, and trade flows. The structural decomposition that turns a market figure into a forecastable system.
TAM · SAM · SOM reconciliation
vs reported: ⚠ flagged (90% variance)01TAMTotal addressable
$5.9B
Global ceiling
Method
Top-down: served market × broader-addressable multiplier
Includes adjacent segments and currently-unaddressed geography that the served market could expand into without crossing into a different category.
- Industry-typical TAM/served ratio applied to current served-market size
- No new product-class expansion modeled
02SAMServiceable addressable
$3.0B
50% of TAM
Method
Bottom-up: served market × realistic-reach multiplier
Reflects served customers that could be reached without changing distribution model, regulatory clearance, or channel structure.
- Existing channel mix preserved
- Regulatory clearance unchanged
03SOMServiceable obtainable
$425M
14% of SAM · 3-yr capture
Method
Achievable share within 5-year window
Realistic share for a top-quartile entrant or established player extending reach within 5 years.
- Top-quartile execution
- Stable competitive dynamics
Bottom-up reconciliation cross-checks the reported market size. Reported 2025 size $4.2B vs SOM estimate $425M — 90% variance. Large variance flags assumptions to re-examine.
Value chain map
6 layers · upstream → downstream01 · UpstreamLow margin
Raw materials & components
Commoditized; multi-source qualification limits supplier power on most categories.
Players
Polymer / metal / nitinol suppliersSterile-component manufacturers
02 · UpstreamMedium margin
Specialty intermediates
IP-protected formulations; switching costs material.
Players
Drug-eluting stent platform suppliersImplantable-grade-polymer suppliers
03 · MidstreamHigh margin
Device manufacturers
Brand, regulatory clearance, and clinical evidence drive margin.
Players
Top-25 medical-device incumbentsSpecialty challengers
04 · MidstreamMedium margin
Contract sterile manufacturing
ISO 13485 qualification gates entry.
Players
Specialty CMOsIn-house manufacturing arms
05 · DownstreamLow margin
Distribution + GPO
GPO contracts deliver pricing leverage to hospital buyers; thin distributor margin.
Players
VizientPremierHealthTrustspecialty distributors
06 · DownstreamMedium margin
Hospitals + ambulatory centers
End-customer; reimbursement and patient mix drive economics.
Players
IDN hospital systemsASCsspecialty practices
Chapters covering size
7
Of 31 total in the commissioned report
Pages
62+
Across pricing, TAM/SAM/SOM, value chain, trade
Data sources
26
Filings · sovereign stats · industry trade · primary
Validation models
10
Coherence + plausibility scoring per figure
Strategic framing
Buyer · tech · competition · scenarios.
Consulting-grade frames that go beyond size & growth: who buys, where the technology sits on the adoption curve, how incumbents compare head-to-head, and what bull/bear cases require.
Buyer persona · decision unit
Primary buyer
Budget
Cycle
Influencers
01
02
03
04
05
Purchase criteria · weighted
%
%
%
%
%
Channel mix
GPO national contracts
%
Direct hospital tender
%
IDN consortium agreement
%
Retail / specialty distribution
%
Decision-unit model. Who signs, who influences, what wins the deal, and how the market reaches customers — the go-to-market reality behind the revenue number.
Persona derived from editorial consensus across primary sources. Not based on primary survey research. Commissioned reports include optional buyer-interview add-ons.
Technology maturity
Overall: Maturation with selective sub-tech inflectionemerging
growth
mature
decline
Sub-technologies
Image-guided procedural systemsMainstream
%
AI-augmented diagnosticsInflection
%
Robotic / autonomous procedural assistEarly adoption
%
Stage-and-adoption framing. Each sub-technology positioned by stage + adoption %. Disruption watch flags tech that could reframe the competitive set.
Scenario analysis
CAGR · 2025–36
7.2%
Reported consensus
2030
$6.0B
2036
$9.1B
2.1× vs 2025Must hold for this case
- 1Status-quo regulatory and reimbursement environment
- 2Industry-typical price-decline trajectory
- 3No major segment expansion
Base case matches the reported CAGR. Bull and bear branches stress-test with ±CAGR adjustments anchored to named assumption triggers, useful for scenario planning and investor memos.
What Is Driving the Affinity Chromatography Market? Trends, Drivers & Restraints (2026)
3 primary growth drivers and 2 structural restraints shape the affinity chromatography market in 2026. Monoclonal-antibody pipeline volume is the lead tailwind, while Resin cost and ligand scarcity is the principal counter-force. Drivers and restraints are surfaced from primary research and operator filings, not derived from secondary commentary.
Market dynamics
Driver
Monoclonal-antibody pipeline volume
650+ mAbs in clinical trials globally; commercial-scale Protein A capture is the volume driver.
Driver
Biosimilar adoption ramp
Biosimilar penetration of Humira / Avastin / Herceptin scaling globally; biosimilars use the same affinity-purification workflow as branded mAbs.
Driver
Cell + gene therapy emerging demand
Lentivirus / AAV vector purification is the next growth wedge, affinity capture for these modalities is in early commercialization.
Restraint
Resin cost and ligand scarcity
Protein A resin (the workhorse for monoclonal antibody capture) prices $10k–18k/L; aging columns require costly replacement at 200-cycle intervals. Resin economics are the dominant binding constraint on bioprocess unit cost.
Restraint
Scalability ceiling for large-volume biologics
Single-pass tangential-flow filtration and continuous chromatography are eroding affinity's volume share for blockbuster mAbs at >5,000 L bioreactor scale, where conventional packed-bed columns hit pressure-drop and cycle-time limits.
Which Region Leads the Affinity Chromatography Market? North America at 44%
North America is the largest regional market for the affinity chromatography, at 44% of 2025 revenue ($1.9B). Europe follows at 26% ($1.1B). Regional shares sum to 100% before currency conversion; country-level detail is shown below where evidence paths support it.
Regional analysis
01North America$1.9B
44%
02Europe$1.1B
26%
03Asia Pacific$935M
22%
04Rest of World$340M
8%
Country analysis
| Country | Size (USD M) | CAGR | Share |
|---|---|---|---|
| USUnited States | $1.8B | 5.5% | 42.0% |
| CNChina | $595M | 7.5% | 14.0% |
| DEGermany | $297M | 5.0% | 7.0% |
| JPJapan | $255M | 4.5% | 6.0% |
| GBUnited Kingdom | $212M | 5.5% | 5.0% |
| FRFrance | $170M | 5.5% | 4.0% |
| BRBrazil | $127M | 6.5% | 3.0% |
| ROWRest of world | $807M | 6.0% | 19.0% |
What Is the Affinity Chromatography Market Forecast to 2036? 7.2% CAGR, 2026–2036
The affinity chromatography market is forecast to grow from $4.2B in 2025 to $9.1B by 2036, a CAGR of 7.2%. Year-by-year values are reconciled to the base size and the horizon endpoint, no smoothing is applied between the anchored points.
Year-by-year forecast
| Year | Market size (USD M) | YoY growth |
|---|---|---|
| 2025 | $4.2B | — |
| 2026 | $4.6B | +7.2% |
| 2027 | $4.9B | +7.2% |
| 2028 | $5.2B | +7.2% |
| 2029 | $5.6B | +7.2% |
| 2030 | $6.0B | +7.2% |
| 2031 | $6.4B | +7.2% |
| 2032 | $6.9B | +7.2% |
| 2033 | $7.4B | +7.2% |
| 2034 | $7.9B | +7.2% |
| 2035 | $8.5B | +7.2% |
| 2036 | $9.1B | +7.2% |
Industry structure
Porter forces · SWOT.
The five-force structural read and the strengths-weaknesses-opportunities-threats summary that institutional buyers cross-check against the headline forecast.
Porter five forces
Rivalry 4/5 — Established medical-device incumbents compete head-to-head on clinical evidence and ASP within a tight set of named players. Consolidation has trimmed the field but margin discipline is uneven.
New entrants 2/5 — FDA 510(k) / PMA pathways and clinical trial costs gate entry. Capital intensity, GPO contract leverage, and hospital relationships further raise the barrier.
Buyer power 4/5 — Concentrated GPO buying coalitions and IDN consolidation deliver durable price pressure; commercial payers and CMS reimbursement caps amplify it.
SWOT summary
Strengths
Reimbursed indication breadth
affinity chromatography procedures are CMS NCD covered with stable commercial-payer adoption; reimbursement is a tailwind not a question.
Tier-1 clinical evidence base
Multi-center RCTs and large registries underwrite physician confidence and payer coverage decisions.
Weaknesses
ASP compression in mature segments
Generic / second-source competition trims 3–5%/yr ASP on the volume tier; product-line refresh cadence has to keep pace.
Capital-equipment cycle dependency
Hospital cap-ex pull-forward (Covid-era) has matured; replacement cycles slow into 2026–2028.
Opportunities
Indication expansion via new clinical trials
Trials extending eligibility (intermediate-risk, extended window) are the canonical upside lever.
Emerging-market adoption ramp
China VBP plus India and Brazil regulatory tailwinds open volume runway at 2–3× domestic growth.
Threats
CMS reimbursement re-pricing
Bundled-payment expansion plus site-neutral resets compress ASP outside Tier-1 indications.
Generic / Chinese DES-class competition
Sub-$1,000 imports erode margin in EM and in cost-sensitive US contracts.
What's Changed Recently? Recent Industry News & Developments
3 recent developments tracked across the affinity chromatography industry: product launches, regulatory updates, and clinical or commercial milestones, most recent dated Q2 2024.
Recent industry events
P
Q2 2024
Search ↗Cytiva (Danaher) launched MabSelect VL platform, higher-capacity Protein L resin targeted at bispecifics, Fab fragments, and kappa-light-chain-containing antibody variants.
R
Q4 2024
Search ↗FDA approved 19 biosimilars in 2024, all using affinity-capture-based purification, sustaining recurring resin demand.
P
Q1 2025
Search ↗Continuous chromatography pilot deployments at Roche / Genentech reaching commercial scale, partial substitution risk for traditional packed-bed at high titer.
Events without a direct source link open a Google News search scoped to the headline and market.
Frequently Asked Questions about the Affinity Chromatography Market
Frequently asked questions
$4.2B in 2025, scaling to $9.1B by 2036 on a 7.2% CAGR. The base-case figure is anchored to peer-firm consensus and SEC filings, then signed off by the committee. Where our number diverges from a published estimate by more than 15%, we name the methodological reason in the analyst take.
Cytiva (Danaher) holds 25.0% on roughly $1.1B of sector revenue. Add Thermo Fisher at 20.0% and Merck KGaA at 15.0% and the top three control 60%. The remaining 40% is split across regional incumbents and a long tail of acquisition candidates for any of the top three.
Cross-linked agarose (Sepharose-class, 4–6% CL) at 52% of value. The cube spans by ligand chemistry (resin sub-family) / by matrix / bead backbone / by end application (process stage) / by product format (procurement sku) / by geography of end-use (demand sink), with sub-segment shares anchored to peer-firm breakdowns and committee-reviewed sizing. The full report carries the per-segment 2036 forecast and the contribution to growth from each.
North America ran 44% of the 2025 pool, roughly $1.9B in absolute terms. Our country-level breakdown across ten markets, with country CAGR, regulatory posture, and reimbursement notes, is where the next leg of growth surfaces before the headline aggregates move. That sits in the full report.
Top of our list on the upside: monoclonal-antibody pipeline volume, with biosimilar adoption ramp a close second. The binding constraint over the next twenty-four months is resin cost and ligand scarcity. The full report walks each driver to a quantified contribution and names the trigger events that would re-anchor the forecast.
Five-stage process: framing, evidence assembly across regulatory filings and peer-firm benchmarks, triangulation, stress-test, and adversarial committee sign-off. Nothing publishes without the committee. Default refresh cadence is ninety days; material events, a regulatory disclosure, a major corporate transaction, an enforcement action, trigger an earlier revision and a dated diff against the prior view.
Add-on chapters · from $79
Commission this report — then attach Layers.
Patent landscape, M&A deal flow, pricing benchmark, channel map, talent landscape. Pick at checkout. Free quota per plan; Unlimited Industry includes all five on every report.
Commission the full report
Pick the scope. Keep the research.
One-time purchase. No subscription traps. Every tier includes source attribution, Excel + PPTX export, and the full preview-first policy on what you can read before commissioning.
Instant access on demand
Read everything before you commission
90-day refresh included
Strategic Brief
Just this market
$799
one-time
- 30-chapter commissioned report
- Top-25 company profiles
- Independent reconciliation + red-team review
- Interactive chat with your report
- Live scenario modeler (CAGR sliders)
- PDF + PowerPoint + Excel export
- Provenance ledger · source trace
- 90-day refresh included
5-pack bundle
Most popularAny 5 markets in Healthcare
$1,999
$400 per report
- Everything in Single report, ×5
- Any 5 markets in the same industry
- Cross-market comparison view
- Shared methodology note + side-by-side
- Change alerts + comments on each report
- Tokenised share links for each
- Rolling 90-day refresh on all 5
- Email support
10-pack bundle
Any 10 markets in Healthcare
$2,999
~$300 per report
- Everything in 5-pack bundle, ×2
- Any 10 markets in the same industry
- 10-market comparison dashboard
- Volume-tier per-report price
- Priority generation queue
- Shared refresh window for all 10
- Bulk PDF/PPTX export
- Email support
Industry unlimited
Every Healthcare market, 5 years
$8,999
5-year access · included
- Unlimited reports in this industry
- 5 years free updates + Senior Analyst Support, included
- Priority queue for new commissions
- Quarterly industry outlook included
- Living / auto-refresh on every report
- Company-tracker dashboard
- White-label branding (logo + palette)
- Team seats + shared workspace
Add Senior Analyst Support, from $89/mo
Quarterly refresh, watchlist alerts, and async analyst questions on your owned reports. Tracker / Strategist / Insider tiers, billed monthly, cancel any time.
Prices in USD. Invoices supported for orders over $1,999. Refund policy · Terms
Platform review · LinkedIn · Q2 2026
“…I appreciate how it compiles data from multiple sources and delivers a complete analysis with a great summary explaining the information and conclusions.…”
Marjorie de Souza
CMO · Head of Marketing · Latin America & Global